Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(38 sites)

United States

Alabama Kidney Research, Alabaster, Alabama

UAB Nephrology Research at CH19, Birmingham, Alabama

Kaiser Permanente Los Angeles Medical Center, Los Angeles, California

UCSF Clinical Research Center at Parnassus, San Francisco, California

Nephrology & Hypertension Associates, PC, Middlebury, Connecticut